Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Oncology Institute (TOI) Gross Margin: 2020-2024

Historic Gross Margin for Oncology Institute (TOI) over the last 5 years, with FY2024 value amounting to 52.5%.

  • Oncology Institute's Gross Margin fell 5300.0% to 13.85% in Q3 2025 from the same period last year, while for Sep 2025 it was 67.69%, marking a year-over-year increase of 283600.0%. This contributed to the annual value of 52.5% for FY2024, which is 83300.0% up from last year.
  • Per Oncology Institute's latest filing, its Gross Margin stood at 52.5% for FY2024, which was up 83300.0% from 44.17% recorded in FY2023.
  • Over the past 5 years, Oncology Institute's Gross Margin peaked at 52.5% during FY2024, and registered a low of 44.17% during FY2023.
  • Moreover, its 5-year median value for Gross Margin was 48.94% (2020), whereas its average is 48.65%.
  • Its Gross Margin has fluctuated over the past 5 years, first tumbled by -44100bps in 2022, then skyrocketed by 83300bps in 2024.
  • Annual analysis of 5 years shows Oncology Institute's Gross Margin stood at 48.94% in 2020, then rose by 4bps to 51.03% in 2021, then fell by -9bps to 46.63% in 2022, then fell by -5bps to 44.17% in 2023, then grew by 19bps to 52.5% in 2024.
  • Its last three reported values are 52.5% in FY2024, 44.17% for FY2023, and 46.63% during FY2022.